T-cell responses at baseline and during therapy with peginterferon-α and ribavirin are not associated with outcome in chronic hepatitis C infected patients

Antiviral Research

Volumn 87, Issue 3, 2010, Pages 353-360

  Arends, Joop E ^a   Claassen, Mark A A ^b   van den Berg, Charlotte H S B ^a,c   Nanlohy, Nening M ^a   van Erpecum, Karel J ^a   Baak, Bert C ^d   Hoepelman, Andy I M ^a   Boonstra, Andre ^b   van Baarle, Debbie ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Hepatitis C virus; Peginterferon ; Ribavirin

Indexed keywords

GAMMA INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL;

HEPATITIS C VIRUS;

EID: 77955842714     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.06.002     Document Type: Article

References (55)

1. Aberle J.H., Perstinger G., Weseslindtner L., Sinzinger U., Gurguta C., Steindl-Munda P., Kundi M., Popow-Kraupp T., Ferenci P., Holzmann H. CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance. J. Infect. Dis. 2007, 195:1315-1319.
2. Aghemo A., Rumi M.G., Monico S., Prati G.M., D'Ambrosio R., Donato M.F., Colombo M. The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. Antivir. Ther. 2009, 14:577-584.
3. Arends J.E., Stuart J.C., Baak L.C., van der Ende M.E., van Erpecum K.J., Simons C.P., Boland G.J., van Baarle D., Hoepelman A.I. Plasma HCV-RNA decline in the first 48h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy. J Viral Hepat. 2009, 16(12):867-875.
4. Barnes E., Gelderblom H.C., Humphreys I., Semmo N., Reesink H.W., Beld M.G., van Lier R.A., Klenerman P. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J. Infect. Dis. 2009.
5. Barnes E., Harcourt G., Brown D., Lucas M., Phillips R., Dusheiko G., Klenerman P. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002, 36:743-754.
6. Benito J.M., Lopez M., Lozano S., Martinez P., Kuroda M., Gonzalez-Lahoz J., Soriano V. Phenotype and functional characteristics of HIV-specific cytotoxic CD8+ T cells in chronically infected patients: dual effects of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 2003, 34:255-266.
7. Boonstra A., van der Laan L.J., Vanwolleghem T., Janssen H.L. Experimental models for hepatitis C viral infection. Hepatology 2009, 50:1646-1655.
8. Brinkmann V., Geiger T., Alkan S., Heusser C.H. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J. Exp. Med. 1993, 178:1655-1663.
9. Burton J.R., Klarquist J., Im K., Smyk-Pearson S., Golden-Mason L., Castelblanco N., Terrault N., Rosen H.R. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J. Hepatol. 2008, 49:329-338.
10. Caetano J., Martinho A., Paiva A., Pais B., Valente C., Luxo C. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J. Virol. 2008, 82:7567-7577.
11. Capa L., Soriano V., Garcia-Samaniego J., Nunez M., Romero M., de M.C., Cascajero A., Munoz F., Gonzalez-Lahoz J., Benito J.M. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients. Antivir. Ther. 2007, 12:459-468.
12. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead-Loudis J., McHutchison J.G., Alter H.J., Chisari F.V. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001, 33:267-276.
13. Claassen M.A., de Knegt R.J., Tilanus H.W., Janssen H.L., Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J. Hepatol. 2010, 52:315-321.
14. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118:346-355.
15. Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandhi R.T., Chung R.T., Walker B.D. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 2002, 76:12584-12595.
16. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J. Antimicrob. Chemother. 2004, 53:15-18.
17. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
18. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
19. Grabowska A.M., Lechner F., Klenerman P., Tighe P.J., Ryder S., Ball J.K., Thomson B.J., Irving W.L., Robins R.A. Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur. J. Immunol. 2001, 31:2388-2394.
20. Gruner N.H., Gerlach T.J., Jung M.C., Diepolder H.M., Schirren C.A., Schraut W.W., Hoffmann R., Zachoval R., Santantonio T., Cucchiarini M., Cerny A., Pape G.R. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J. Infect. Dis. 2000, 181:1528-1536.
21. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004, 140:346-355.
22. Hoffmann R.M., Diepolder H.M., Zachoval R., Zwiebel F.M., Jung M.C., Scholz S., Nitschko H., Riethmuller G., Pape G.R. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995, 21:632-638.
23. Ishii S., Koziel M.J. Immune responses during acute and chronic infection with hepatitis C virus. Clin. Immunol. 2008, 128:133-147.
24. Jansen C.A., Piriou E., De C., van I., Lange D.K., Miedema J.M., van Baarle F.D. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antivir. Ther. 2006, 11:105-116.
25. Jansen C.A., van Baarle D., Miedema F. HIV-specific CD4+ T cells and viremia: who's in control?. Trends Immunol. 2006, 27:119-124.
26. Kamal S.M., Fehr J., Roesler B., Peters T., Rasenack J.W. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002, 123:1070-1083.
27. Kaplan D.E., Sugimoto K., Ikeda F., Stadanlick J., Valiga M., Shetty K., Reddy K.R., Chang K.M. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology 2005, 41:1365-1375.
28. Lasarte J.J., Garcia-Granero M., Lopez A., Casares N., Garcia N., Civeira M.P., Borras-Cuesta F., Prieto J. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology 1998, 28:815-822.
29. Lauer G.M., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., Schulze zur Wiesch J., Paranhos-Baccala G., Sheridan I., Casson D.R., Reiser M., Gandhi R.T., Li B., Allen T.M., Chung R.T., Klenerman P., Walker B.D. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J. Virol. 2005, 79:12979-12988.
30. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 1998, 161:1947-1953.
31. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
32. Marinho R.T., Pinto R., Santos M.L., Lobos I.V., Moura M.C. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. J. Viral Hepat. 2004, 11:206-216.
33. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 1996, 98:706-714.
34. Nelson D.R., Marousis C.G., Ohno T., Davis G.L., Lau J.Y. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998, 28:225-230.
35. Neumann-Haefelin C., Blum H.E., Chisari F.V., Thimme R. T cell response in hepatitis C virus infection. J. Clin. Virol. 2005, 32:75-85.
36. Neumann-Haefelin C., Timm J., Spangenberg H.C., Wischniowski N., Nazarova N., Kersting N., Roggendorf M., Allen T.M., Blum H.E., Thimme R. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 2008, 47:1824-1836.
37. Penna A., Missale G., Lamonaca V., Pilli M., Mori C., Zanelli P., Cavalli A., Elia G., Ferrari C. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology 2002, 35:1225-1236.
38. Pilli M., Zerbini A., Penna A., Orlandini A., Lukasiewicz E., Pawlotsky J.M., Zeuzem S., Schalm S.W., von W.M., Germanidis G., Lurie Y., Esteban J.I., Haagmans B.L., Hezode C., Lagging M., Negro F., Homburger Y., Neumann A.U., Ferrari C., Missale G. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007, 133:1132-1143.
39. Piriou E.R., van Dort K., Nanlohy N.M., van Oers M.H., Miedema F., van Baarle D. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects. Eur. J. Immunol. 2005, 35:796-805.
40. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., Plebanski M., Akinwunmi P., Everaere S., Watkins K.R., Voss G., Tornieporth N., Alloueche A., Greenwood B.M., Kester K.E., McAdam K.P., Cohen J., Hill A.V. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat. Med. 2004, 10:406-410.
41. Rehermann B., Naoumov N.V. Immunological techniques in viral hepatitis. J. Hepatol. 2007, 46:508-520.
42. Rosen H.R., Miner C., Sasaki A.W., Lewinsohn D.M., Conrad A.J., Bakke A., Bouwer H.G., Hinrichs D.J. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002, 35:190-198.
43. Rosen H.R., Weston S.J., Im K., Yang H., Burton J.R., Erlich H., Klarquist J., Belle S.H. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007, 46:350-358.
44. Ruys T.A., Nanlohy N.M., van den Berg C.H., Hassink E., Beld M., van de Laar T., Bruisten S., Wit F., Krol A., Prins M., Lange J., van Baarle D. HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance. J. Viral Hepat. 2008, 15:409-420.
45. Scherrenburg J., Piriou E.R., Nanlohy N.M., van Baarle D. Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis. Clin. Exp. Immunol. 2008, 153:231-239.
46. Tang K.H., Herrmann E., Cooksley H., Tatman N., Chokshi S., Williams R., Zeuzem S., Naoumov N.V. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J. Hepatol. 2005, 43:776-782.
47. Thimme R., Neumann-Haefelin C., Boettler T., Blum H.E. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol. Chem. 2008, 389:457-467.
48. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., Carosi G., Sasadeusz J., Katlama C., Montaner J., Sette H., Passe S., De Pamphilis J., Duff F., Schrenk U.M., Dieterich D.T. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 2004, 351:438-450.
49. Tough D.F., Sun S., Zhang X., Sprent J. Stimulation of naive and memory T cells by cytokines. Immunol. Rev. 1999, 170:39-47. 39-47.
50. Urbani S., Amadei B., Tola D., Pedrazzi G., Sacchelli L., Cavallo M.C., Orlandini A., Missale G., Ferrari C. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J. Hepatol. 2008, 48:548-558.
51. van den Berg C.H., Ruys T.A., Nanlohy N.M., Geerlings S.E., van der Meer J.T., Mulder J.W., Lange J.A., van Baarle D. Comprehensive longitudinal analysis of hepatitis C virus (HCV)-specific T cell responses during acute HCV infection in the presence of existing HIV-1 infection. J. Viral Hepat. 2009, 16:239-248.
52. Vertuani S., Bazzaro M., Gualandi G., Micheletti F., Marastoni M., Fortini C., Canella A., Marino M., Tomatis R., Traniello S., Gavioli R. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 2002, 32:144-154.
53. Walker L.J., Sewell A.K., Klenerman P. T cell sensitivity and the outcome of viral infection. Clin. Exp. Immunol. 2010, 159:245-255.
54. Wong D.K., Dudley D.D., Afdhal N.H., Dienstag J., Rice C.M., Wang L., Houghton M., Walker B.D., Koziel M.J. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J. Immunol. 1998, 160:1479-1488.
55. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., Ibranyi E., Weiland O., Noviello S., Brass C., Albrecht J. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 2006, 44:97-103.